Navigation Links
INTERMACS: Total Artificial Heart Bridge-to-Transplant Rate 2x Higher ,at 6 Months Than BiVADS and LVADs
Date:5/12/2009

Replacing Both Ventricles with the Total Artificial Heart Eliminates Complications Including Right Heart Failure

Tucson, Ariz. (Vocus) May 12, 2009 -- According to INTERMACS data recently published in SynCardia’s 2008 Annual Report, the SynCardia temporary CardioWest™ Total Artificial Heart has a bridge-to-transplant rate of 72% at 6 months. This is double the bridge-to-transplant rate for Biventricular Assist Devices (BiVADS) at 36% and Left Ventricular Assist Devices (LVADs) at 27% (see Chart 1).

Unlike BiVADs and LVADs which assist the heart ventricle(s), the Total Artificial Heart replaces both dying heart ventricles. This eliminates complications caused by a dying heart including right native heart failure.

According to INTERMACS, 8% of BiVAD patients and 10% of LVAD patients experience right heart failure (see Chart 2). These patients often require treatment with inotropes and/or implantation of a right ventricular assist device. Total Artificial Heart patients are not subject to right native heart failure because the dying heart ventricles have been removed.

INTERMACS is the US national registry for patients with mechanical circulatory support devices that treat advanced heart failure. By applying uniform definitions and standards, INTERMACS levels the playing field for all mechanical circulatory support devices. INTERMACS tracks patient survival, adverse events and cause of death over time by patient profile, device and device category.

INTERMACS was created as a joint effort of the National Heart, Lung and Blood Institute (NHLBI), the Centers for Medicare and Medicaid Services (CMS), the Food and Drug Administration (FDA) and the United Network for Organ Sharing (UNOS) among others.

Originally designed as a permanent replacement heart, the Total Artificial Heart is currently approved as a bridge to human heart transplant for patients dying from end-stage biventricular failure. The Total Artificial Heart is the only device that provides immediate, safe blood flow of up to 9.5 L/min through both ventricles.

The SynCardia Total Artificial Heart is the first and only FDA, Health Canada and CE Mark approved Total Artificial Heart in the world. There have been more than 790 implants of the Total Artificial Heart, accounting for more than 160 patient years of life on the device.

###

Read the full story at http://www.prweb.com/releases/2009/05/prweb2404984.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Total Artificial Heart Patient 3rd in the World to Receive Dual Transplants
2. Extra payments to Medicare Advantage plans to total $11.4 billion in 2009
3. Swine Flu Cases Now Total 7: CDC
4. NuVasive Announces Acquisition of Cervical Total Disc Replacement Device
5. SynCardia Introduces New 12-lb Freedom Discharge Driver Designed to Provide Quality 'Lifestyle' for Total Artificial Heart Patients
6. Squeezing Calories? New Study Finds That Low-Fat Popcorn Before Lunch Does Not Increase Total Calorie Intake
7. FCP Announces Total Healthcare Integration Solution (THIS) Powered by TIBCO
8. Closing Open Heart Surgery: Saint Josephs Performs Georgias First Totally-Closed, Beating Heart Bypass Surgery
9. Hip Resurfacing Championed as a Bone-Preserving Alternative to Total Hip Replacement
10. MEDRAD Multi Vendor Service Launches TotalRepair(SM) on Select Ultrasound Probes
11. Highline Data Analysis Shows Year-over-Year P&C Industry Net Income Down 67.7%, Life Industry Net Unrealized Capital Losses Totaled $51.7 billion in 2008
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
INTERMACS: Total Artificial Heart Bridge-to-Transplant Rate 2x Higher ,at 6 Months Than BiVADS and LVADs
(Date:12/2/2016)... ... 02, 2016 , ... Dr. Raffi Hovsepian, a leading plastic, ... 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The prestigious ... experience, and professional associations. , One the most frequently honored surgeons in ...
(Date:12/2/2016)... ... 02, 2016 , ... Mediaplanet is proud to announce the ... the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and ... 6 years in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned ...
(Date:12/2/2016)... ... December 02, 2016 , ... The PAINWeekEnd Regional Conference will ... Spa in Honolulu, offering local frontline clinicians the opportunity to extend their certified ... demand for supplemental training related to pain management has surged dramatically in recent ...
(Date:12/2/2016)... ... 02, 2016 , ... Sourced from the Isbre Springs beneath the 5,000 year ... natural purity of just 6 ppm TDS (Total Dissolved Solids) in addition to its ... available in several ShopRite and FoodTown stores in NJ and received rave comments from ...
(Date:12/2/2016)... ... , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, Texas, has ... Prophecy. Yisrayl says this generation, known as the Last Generation, started in 1934 A.Y. ... line up exactly with Bible Prophecy – a protected way for those who will ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... 2016   Pairnomix, LLC, a genetic research company ... by the White House, today announced that findings from its ... of candidate therapies for a patient with epileptic encephalopathy caused ... presented at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process ...
(Date:12/4/2016)... , Dec. 3, 2016  Results from the Phase ... an anti-P-selectin antibody, reduced the median annual rate of ... placebo (1.63 vs 2.98, p=0.010) in patients with or ... the data are being featured in the official press ... Hematology (ASH) Annual Meeting and presented during the Plenary ...
(Date:12/4/2016)... 3, 2016  Findings from a Novartis clinical ... an investigational chimeric antigen receptor T cell (CAR ... adult patients with B-cell acute lymphoblastic leukemia (ALL) ... at the 58th American Society of Hematology (ASH) ... The global Phase II study found that 82% ...
Breaking Medicine Technology: